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1660Background: Thoracic artificial lungs have been proposed as a bridge to transplant in patients with end-stage
lung disease. Systemic embolic complications can occur after thoracic artificial lung attachment in the pulmo-
nary artery to left atrium configuration. Therefore, we evaluated the function of a compliant thoracic artificial
lung attached via the proximal pulmonary artery to distal main pulmonary artery configuration.
Methods: The compliant thoracic artificial lung was attached to 5 sheep (63  0.9 kg) in the proximal pulmo-
nary artery to distal main pulmonary artery configuration. Device function and animal hemodynamics were as-
sessed at baseline and with approximately 60%, 75%, and 90% of cardiac output diverted to the compliant
thoracic artificial lung. At each condition, dobutamine (0 and 5 mg$kg1$min1) was used to simulate rest
and exercise conditions.
Results: At rest, cardiac output decreased from 6.20  0.53 L/min at baseline to 5.40  0.43, 4.66  0.31, and
4.05 0.27 L/min with 60%, 75%, and 90% of cardiac output to the compliant thoracic artificial lung, respec-
tively (P<.01 for each flow diversion vs baseline). During exercise, cardiac output decreased from 7.85  0.70
L/min at baseline to 7.46 0.55, 6.93 0.51, and 5.96 0.44 L/min (P¼ .82, P¼ .19, and P<.01 with respect
to baseline) with 60%, 75%, and 90% of cardiac output to the compliant thoracic artificial lung, respectively.
The artificial lung resistance averaged 0.46  0.02 and did not vary significantly with blood flow rate.
Conclusions: Use of a compliant thoracic artificial lung may be feasible in the proximal pulmonary artery to
distal main pulmonary artery setting if its blood flow is held at less than 75% of cardiac output. To ensure a de-
crease in cardiac output of less than 10%, a blood flow rate less than 60% of cardiac output is advised. (J Thorac
Cardiovasc Surg 2013;145:1660-6)Lung transplantation provides the possibility of substan-
tially increased survival for patients with end-stage pulmo-
nary disease. Unfortunately, the demand for donor organs
continues to exceed the current supply. Although changes
in the donor organ allocation system have decreased waiting
list mortality, there were still 266 waiting list deaths in
2008.1 To address this issue, thoracic artificial lungs
(TALs) have been proposed as a bridge to lung
transplantation.
Numerous case reports have shown that long-term extra-
corporeal membrane oxygenation (ECMO) can be used to
bridge patients to lung transplantation.2-5 However,
cannulation and the ECMO circuit could make
pretransplant rehabilitation more difficult when compared
with TAL use. ECMO is also associated with bloode Department of General Surgery,a University of Michigan Medical Center,
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The Journal of Thoracic and Cardiovascular Surelement activation, hemolysis, and platelet consumption,
which can lead to increased transfusions, systemic
inflammatory response, and organ system failure.6
Use of a paracorporeal, pumpless TAL could enhance pa-
tient mobility preoperatively, cause fewer hematologic de-
rangements, and expedite post-transplant recovery in
patients who are bridged to lung transplantation. A previous
study of the BioLung TAL (MC3 Corp, AnnArbor,Mich) in
normal sheep has shown that this device is capable of pro-
viding respiratory support for a 30-day period when used
in the pulmonary artery to left atrium (PA-LA) configura-
tion.7 Moreover, these studies demonstrated stable platelet
counts and no evidence of hemolysis, suggesting better bio-
compatibility compared with ECMO.7 There is no pur-
posely designed TAL available clinically. However, 6
patients have been bridged to transplant using a Novalung
ILA (Novalung GmbH, Hechingen, Germany) in a PA-LA
configuration.8-10 The PA-LA configuration can decrease
the workload of the right ventricle (RV) by providing an al-
ternate pathway for blood flow. However, potentially cata-
strophic systemic embolic complications, such as stroke,
could occur.9,10
An alternative configuration, the proximal PA to distal PA
(PA-PA) configuration has a low risk for systemic embolic
events. This approach is limited by the increased workload
of the RV having to pump sequentially through the devicegery c June 2013
Abbreviations and Acronyms
CO ¼ cardiac output
cTAL ¼ compliant thoracic artificial lung
CVP ¼ central venous pressure
ECMO ¼ extracorporeal membranous oxygenation
MAP ¼ mean arterial pressure
PA ¼ pulmonary artery
PA-LA ¼ pulmonary artery to left atrium
PA-PA ¼ proximal pulmonary artery to distal
pulmonary artery
pPAP ¼ proximal pulmonary artery pressure
PVR ¼ pulmonary vascular resistance
RV ¼ right ventricle
TAL ¼ thoracic artificial lung
Scipione et al Cardiothoracic Transplantationand the native lungs. Therefore, presence of pulmonary hy-
pertension would be a relative contraindication to this at-
tachment configuration. However, a significant subset of
lung transplant candidates with chronic respiratory insuffi-
ciency do not have pulmonary hypertension (mean PA
pressure>25 mm Hg), including 69% of candidates with
idiopathic pulmonary fibrosis,11 50% with chronic obstruc-
tive pulmonary disease,12 and 37% with cystic fibrosis.13
Nonetheless, the TAL must have a stable, low resis-
tance for this approach to be feasible. In the current study,
a new compliant thoracic artificial lung (cTAL) design is
examined for this setting. The cTAL uses a compliant
housing with a gradual inlet in an attempt to achieve
ultra-low device resistance (0.5 mm Hg/[L/min]) at all
relevant ranges of blood flow through the device. We hy-
pothesized that this device with ultra-low resistance could
be attached in the PA-PA configuration and maintain nor-
mal CO at high device flow rates. If true, this would de-
crease adverse events from systemic emboli in patients
being bridged to lung transplantation. Thus, the current
study examines the hemodynamic effect of PA-PA attach-
ment under various percentages of CO diverted through
the cTAL and under simulated rest and exercise
conditions.T
XMATERIALS AND METHODS
Compliant Thoracic Artificial Lung
A cTAL, consisting of a compliant Biospan (DSM PTG, Berkeley, Ca-
lif) housing and polypropylene fiber bundle, was used in this study
(Figure 1). This devicewas designed and constructed by our research group
at the University of Michigan.14 In this device, blood flows into the inlet
conduit, expands into the inlet manifold, flows through the fiber bundle,
travels through the outlet manifold, and exits through the outlet conduit.
To create the fiber bundle, woven mats of polypropylene fibers with a fiber
diameter of 210 mm were wound into compact bundles with porosity, path
length, frontal area, and surface area of 0.75, 0.038 m, 0.013 m2, and
2.4 m2, respectively.The Journal of Thoracic and CarExperimental Procedure
Five male sheep averaging 63  0.9 kg were used in this study. Animal
numbers were based on similar previous studies.14 All sheep received hu-
mane care in compliance with the ‘‘Guide for the Care and Use of Labora-
tory Animals,’’ and all methods were approved by the University of
Michigan Committee for the Use and Care of Animals. Anesthesia was in-
duced and mechanical ventilation was performed according to previous
published methods.14 A carotid arterial line and left jugular venous line
were placed and then connected to fluid-coupled pressure transducers
(ICU Medical, Inc, San Clemente, Calif) for the continuous monitoring
of mean arterial pressure (MAP) and central venous pressure (CVP).
Amuscle-sparing left anterolateral thoracotomywas performed, and the
fourth rib was removed. The left lung was packed laterally, and the pericar-
dium was incised. The pulmonary artery (PA) was then identified. Dacron
vascular grafts (18 mm; TerumoMedical Corp, AnnArbor, Mich) were sol-
vent bonded to 5/8’’ inner diameter polyvinyl chloride tubing (Fisher Sci-
entific, Pittsburgh, Pa) and used as conduits for artificial lung attachment.
An end-to-side anastomosis was performed between the device outlet con-
duit and the distal PA near the bifurcation. The device inlet end-to-side
anastomosis was then performed on the proximal PA. An ultrasonic peri-
vascular flow probe (Transonic 24AX, Transonic Systems, Inc, Ithaca,
NY) was placed around the PA, proximal to the device inlet graft for mea-
surement (T400, Transonic Systems) of mean PA flow or cardiac output
(CO). A pressure catheter (Becton Dickinson and Co, Franklin Lakes,
NJ) was then inserted at the proximal PA and connected to a transducer
for the display and recording of the proximal PA pressure (pPAP). A Rum-
mel tourniquet was placed around the PA between the inlet and outlet grafts
to allow for the adjustment of flow through the cTAL. Pressure catheters
were inserted into the distal PA near the bifurcation and into the left atrium
to allow for the recording of the distal PA pressure and the left atrial pres-
sure. Before device attachment, 1g of methylprednisolone (Solu-Medrol;
Pfizer, New York, NY) was administered, and the animal was anticoagu-
lated with 100 IU/kg of intravenous sodium heparin (Baxter Healthcare
Corp, Deerfield, Ill) to maintain active clotting times greater than 300
seconds.
The cTAL was primed with heparinized saline (10 U/mL) and then con-
nected to the proximal PA (device inlet) and distal PA (device outlet) grafts
(Figure 2). An ultrasonic flow probe (Transonic 14PXL; Transonic Sys-
tems, Inc) was placed around the inflow conduit to measure (T400; Tran-
sonic Systems Inc) device flow (QcTAL). The cTAL inlet and outlet
pressures (Pin and Pout) were measured by fluid-coupled pressure trans-
ducers. A suction line was attached to the cTAL gas outlet, and 95:5%
O2:CO2 with vaporized isoflurane (1%-3%) was used as the sweep gas
through the gas inlet. Sweep gas flow was adjusted during cTAL use to
maintain the arterial carbon dioxide tension between 35 and 45 mm Hg.
A Hoffmann clamp was placed around the cTAL outlet conduit to restrict
flow through the device. After cTAL attachment, the clamps on the cTAL
inlet and outlet conduits were removed, and the Hoffmann clamp was loos-
ened until 1 L/min flow to the cTAL was achieved. This flow was main-
tained for 10 minutes for equilibration of fluid volumes and any
inflammatory response. Flow to the cTAL was then stopped briefly, and
up to 500 mL of hetastarch and 500 mL of crystalloid were administered
to restore CVP back to pre-cTAL values, if required.
Rest and exercise conditions were then simulated using a continuous
dobutamine (Hospira Inc, Lake Forest, Ill) infusion of 0 and 5
mg$kg1$min1, respectively. At each dose, a data set was acquired at
baseline, with no flow to the device. Thereafter, the clamps were removed
from the cTAL and the Rummel tourniquet was tightened to divert 60%,
75%, and 90% of CO to the cTAL. At each condition, 10 minutes were al-
lowed for equilibration before data were taken. A data set consisted of re-
cording the average values of all blood pressures and flows. In addition,
arterial and device inlet and outlet blood samples were taken and assayed
for pH, carbon dioxide tension, and oxygen tension using an ABL 725
blood gas analyzer (Radiometer Copenhagen, Copenhagen, Denmark).diovascular Surgery c Volume 145, Number 6 1661
FIGURE 1. The cTAL demonstrating the blood and gas flow paths.
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Average blood flows and pressures were used to calculate all resistances.
The CO is equal to the average PA flow rate. cTAL resistance, RcTAL, was
calculated using the following formula:
RcTAL ¼ PinPout
QcTAL
: (1)
The pulmonary vascular resistance (PVR) of the native lungs was calcu-
lated by the following formula:
PVR ¼ dPAPLAP
CO
: (2)
The resistance of the graft anastomoses, Ra, was calculated by analyzing
all the resistive elements in the experimental pulmonary system setup
(Figure 2). Total pulmonary system resistance, RT, is defined as the resis-
tance of combined artificial and natural lung system from the proximal
PA to the left atrium, and is thus calculated as follows:
RT ¼ pPAPLAP
CO
: (3)
Shunt resistance, Rs, is defined as the resistance of the section
of the main PA containing the artificial lung and its anastomoses,
which is in series with the natural lungs. It was thus calculated as
follows:
Rs ¼ RTPVR: (4)FIGURE 2. Experimental pulmonary system setup with all resistive ele-
ments. The shunt includes the anastomoses (Ain and Aout), the cTAL, and
the flow occluder. cTAL,Compliant thoracic artificial lung; pPAP, proximal
pulmonary artery pressure; Ain, inlet anastomosis; Aout, outlet anastomosis;
dPAP, distal pulmonary artery pressure; LAP, left atrial pressure.
1662 The Journal of Thoracic and Cardiovascular SurThe sum of the anastomoses resistances, Ra, is assumed to be in series
with the cTAL resistance, giving the following relationship:
Ra ¼ Rs
f
RcTAL; (5)
In which f is the fraction of CO diverted to the cTAL. The values of RT,
Rs, and Ra were thus calculated at each flow condition.
Statistical analyses were performed using the Statistical Package for the
Social Sciences version 19 (SPSS, Inc, Chicago, Ill). The analysis of base-
line PVR before and after TAL attachment was conducted using a paired
2-tailed Student t test assuming equal variances. To examine whether
cTAL resistance varied significantly with flow rate, a 1-way analysis of var-
iance was performed. For comparisons of mean values of all other depen-
dent variables, linear models with correlated error structures (given the
repeated measures) were fitted to the observed data. Separate models
were fitted for the 0 and 5 mg/kg/min of dobutamine data. Each model in-
cluded fixed effects of flow diversion to examine differences between base-
line and 60%, 75%, and 90% flow diversion. Alternative covariance
structures were compared using information criteria (eg, Akaike informa-
tion criterion, Bayesian information criterion). In most cases, an autore-
gressive covariance structure was found to have the best fit. However,
Toeplitz and diagonal covariance structures were used for PVR and
mean pulmonary artery pressure, respectively. A Bonferroni correction
was applied to the contrasts to prevent increases in type I error rates. All
data are reported as the mean  the standard error.RESULTS
Device Function
The resistance of the cTAL did not change significantly
with flow rate (P ¼ .16), averaging 0.46  0.02 mm Hg/
(L$min1) over the entire range of flows. Because of the rel-
atively high venous saturations (83.1% 1.3%) and lower
hemoglobin (6.11 0.17 g/dL), the gas transfer function of
the lung was never challenged. Arterial blood gas hemoglo-
bin oxygen saturations were maintained at 99% for all of
the conditions. Finally, all of the devices functioned without
a noticeable decrease in gas exchange or increase in resis-
tance. There was no noticeable clot formation within the de-
vice at the conclusion of the experiment.Sheep Hemodynamics
During the early equilibration period, there was an event
due to blood contact with the artificial lung featuring in-
creased PVR and decreased MAP and CO. This is common
to blood-bearing artificial circuits and is normally attributed
to inflammation.6 During this event, PVR increased from
1.61  0.32 mm Hg/(L/min) to 3.13  0.17 mm Hg/(L/
min) (P ¼ .01), CO decreased from 6.58  0.56 L/min to
6.20  0.53 L/min, and MAP decreased from 87.6  6.2
to 80.9  3.9.
Thereafter, CO was 6.20  0.53 L/min at the experimen-
tal baseline and decreased 13% to 5.40  0.34 L/min at
60% flow to the cTAL (P< .01), 25% to 4.66  0.31
L/min at 75% flow to the cTAL (P< .01), and 35% to
4.05  0.27 L/min at 90% flow to the cTAL (P< .01)
(Figure 3, A). After starting dobutamine at 5
mg$kg1$min1, CO increased to 7.85  0.70 L/min atgery c June 2013
FIGURE 3. CO (A) and MAP (B) versus the percentage of CO shunted to
the compliant artificial lung for dobutamine doses of 0 mg/kg/min and 5 mg/
kg/min. BL, Baseline; cTAL, compliant thoracic artificial lung;MAP,mean
arterial pressure.
FIGURE 4. Total pulmonary system resistance, PVR, and shunt resis-
tance at varying percentages of CO diverted to the compliant artificial
lung for dobutamine doses of (A) 0 mg/kg/min and (B) 5 mg/kg/min. RT,
Total pulmonary system resistance; Rs, shunt resistance;Dob, dobutamine;
PVR, pulmonary vascular resistance; BL, baseline; cTAL, compliant
thoracic artificial lung.
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creased with increasing flows to the cTAL, decreasing 5%
to 7.46  0.55 L/min (P ¼ .82), 12% to 6.93  0.51 L/
min (P ¼ .19), and 24% to 5.96  0.44 L/min (P< .01)
with 60%, 75%, and 90% of CO going through the
cTAL, respectively. Other measures of RV dysfunction var-
ied only slightly and were not as sensitive as CO. The CVP
was between 11.4 and 12.5 mm Hg under all conditions and
did not change significantly with attachment mode at 0 or 5
mg/kg/min of dobutamine (P ¼ .08 and P ¼ .59). Lactate
was within normal ranges for the duration of the experiment
(0.8-1.4 mmol/L). The only statistically significant change
was a decrease in lactate with increasing flow the cTAL
with 0 dobutamine (P<.01 vs baseline).
The MAP decreased with increasing flow to the TAL
(Figure 3, B), as did CO. The baseline MAP was 81  4.0
mm Hg and increased slightly to 83  5.7 mm Hg at
60% of cTAL flow (P ¼ .99) before decreasing to
76  6.1 mm Hg (P ¼ .88) and 67  5.0 mm Hg
(P<.05) under 75% and 90% cTAL flow conditions, re-
spectively. Under the simulated exercise condition, theThe Journal of Thoracic and Carbaseline MAP was 84  5.3 mm Hg. This decreased to
80  6.9 mm Hg at 60% cTAL flow (P ¼ .99), 69  2.8
mm Hg at 75% flow to the cTAL (P<.05), and 60  1.3
mm Hg at 90% flow to the cTAL (P<.01).
The cause of diminishing CO and MAP with increasing
flow diversion to the cTAL is increasing RV afterload.
Figure 4 shows the total pulmonary system resistance (RT)
and its 2 subsections, shunt resistance (Rs) and PVR. As
blood flow is diverted to the cTAL, RT increases linearly
at both 0 and 5 mg/kg/min of dobutamine from
3.39  0.38 and 3.01  0.28 mm Hg/(L/min) at baseline
to 6.50  0.14 and 5.10  0.57 mm Hg/(L/min) at 90%
flow to the cTAL. The PVR does not change significantly
with flow diversion (P ¼ .21, .99, and .99 with increasing
cTAL flow in the 0 dobutamine conditions and P ¼ .35,diovascular Surgery c Volume 145, Number 6 1663
FIGURE 5. Mean pPAP versus the percentage of CO shunted to the com-
pliant artificial lung for dobutamine doses of 0 mg/kg/min and 5 mg/kg/min.
BL, Baseline; cTAL, compliant thoracic artificial lung.
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tions). However, as the PA is banded, blood flows increas-
ingly through the higher resistance circuit with the TAL
and its anastomoses. As a result, Rs increases from
0.26  0.34 and 0.78  0.22 mm Hg/(L/min) at baseline
to 3.18  0.32 and 3.04  0.35 mm Hg/(L/min) with
90% of CO going to the TAL with 0 and 5 mg/kg/min, re-
spectively. Finally, the increased resistance was due to in-
creased flow through this high-resistance circuit and not
due to changes in the resistances themselves. Neither RcTAL
nor Ra changed significantly with increasing flow diversion
(P ¼ .42 and P ¼ .11 at 0 mg/kg/min dobutamine and
P ¼ .42 and P ¼ .35 at 5 mg/kg/min dobutamine for RcTAL
and Ra, respectively). The Ra was 2.63  0.43,
2.39  0.17, and 3.06  0.37 mm Hg/(L/min) at 60%,
75%, and 90% diversion at 0 mg/kg/min of dobutamine, re-
spectively, and 2.25  0.54, 2.60  0.63 mm Hg/(L/min),
and 2.88  0.39 mm Hg/(L/min) with 60%, 75%, and
90% diversion at 5 mg/kg/min of dobutamine, respectively.
Because of offsetting changes in CO and RT, pPAP in-
creased only a small amount with increasing flow diversion
(Figure 5). Baseline pPAP was 28  2.0 mm Hg and in-
creased by a statistically insignificant amount (P ¼ .16) to
33  2.5 mm Hg at 90% flow to the cTAL with 0 mg/kg/
min of dobutamine. In a similar fashion, the baseline
pPAP of 32  4.8 mm Hg increased insignificantly
(P ¼ .98) to 38  0.6 mm Hg at 90% flow to the cTAL
with 5 mg/kg/min of dobutamine.DISCUSSION
Several previous studies have examined TAL use in
a PA-PA setting. Lick and colleagues15 used an early pro-
totype of the MC3 BioLung in conscious, normal sheep
with 100% flow diversion, resulting in poor heart function,
including a 50% incidence of right heart failure.15 In1664 The Journal of Thoracic and Cardiovascular Sursurviving sheep, however, heart function improved over
the 7-day study. Thereafter, the BioLung was redesigned
to reduce blood-flow impedance. The result was a device
with an average blood flow resistance of approximately
1.8 mm Hg/(L/min) under simulated blood flow condi-
tions.16 Subsequently, this device was tested in conscious
sheep with acute respiratory distress syndrome, again
with 100% diversion. This study demonstrated an approx-
imate 20% decrease in CO, followed by accommodation
and normalization of CO.17 Sato and colleagues16 tested
the MC3 BioLung in anesthetized sheep and found
a 25% decrease in CO with 100% flow diversion. Perlman
and colleagues18 also tested an early cTAL prototype in 2
groups of anesthetized pigs with 42% or 100% flow diver-
sion. This device had an average blood flow resistance of
1.9 mm Hg/(L/min) under the same conditions as the Bio-
Lung.19 In this setting, CO decreased by 12% and 42%,
respectively.
The goal of the current study was to determine whether
further hemodynamic improvements in PA-PA attachment
were possible using newer, ultra-low impedance TALs.
In vitro studies of this device indicate that resistance is
0.53  0.06 mm Hg/(L/min) at blood flows of 4 L/min,
and compliance was 5.21  0.57 mL/mm Hg.1 This resis-
tance was less than one third of previously published de-
vices, and the compliance was 18% greater than previous
designs.16,19,20 This study confirmed that it is possible to
achieve PA-PA attachment with both significant TAL flow
and minimal impact on hemodynamics. However, CO de-
creased 25% and 12% during rest and exercise conditions
at 75% diversion. As a result, diversion of 60% of CO or
less seems to be a more reasonable level. At 60%, there
was a 13% and 8% decrease in CO at rest and exercise con-
ditions, respectively. This is a level to which the heart could
likely accommodate (see next page).
The CO decrease in the present study is similar to that in
the studies by Sato and colleagues16 and Perlman and col-
leagues,18 despite lower TAL and pulmonary system resis-
tances. Those studies demonstrated a 4 mm Hg/(L/min)
increase in pulmonary system resistance at 100% flow di-
version versus approximately 3.1 mm Hg/(L/min) at 90%
diversion in the current study. A pulmonary system resis-
tance reduction of 0.9 mm Hg/(L/min) should lead to
a 5% to 7% increase in CO,21,22 or only 0.3 to 0.4 L/min.
Thus, the benefits gained from even a large decrease in
TAL resistance are small. Ultimately, the largest
resistance in the system is not the cTAL itself, but that of
the anastomoses. Anastomoses resistances averaged
approximately 2.6 mm Hg/(L/min) in the current study,
similar to that of previous studies,16,21 whereas the cTAL
resistance is now only 0.5 mm Hg/(L/min).
Despite the limited improvement in CO, minimization of
TAL resistance should remain the goal to minimize RV
strain.Threegroups have reported on the use of theNovalunggery c June 2013
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marked pulmonary hypertension.8-10 Average device flow in
these patients ranged from 2.5 to 3.0 L/min with a pressure
decrease of 25 to 30 mm Hg across the device, or a device
resistance of 10 mm Hg/(L/min).10 Although this still al-
lowedmodestRVunloading in the PA-LAsetting, this device
would not be tolerated in a PA-PA configuration.
Despite these limitations, long-term results in conscious
subjects should be significantly better. Two previous studies
have indicated improved CO over 3 to 7 days of PA-PA sup-
port in conscious sheep with 100% flow diversion.16,17 This
may be due to RV accommodation or alleviation of the
effects of both anesthesia and any inflammatory response
to the device. Prolonged anesthesia leads to a progressive
decrease in MAP, RV perfusion, and thus CO.23,24 There
was also an initial event that increased PVR and most
likely a loss in cardiac function before the experimental
period beginning.6,23 These events are common to
blood contact with any blood gas exchanger, be it
cardiopulmonary bypass, ECMO, or the cTAL and are
typically attributed to inflammation.6 This effect typically
resolves within 24 hours after initiation of ECMO,25,26 and
there is no evidence of a significant systemic inflammation
within 24 hours after TAL attachment.7 Thus, as arterial
pressure returns to normal and the inflammation abates, car-
diac function is likely to improve in awake sheep.
As stated earlier, the ability of the device to transfer oxygen
was never challengedbecause of the use of100% inspiredox-
ygen and low hemoglobin. As a result, device outlet oxygen
saturation was always greater than 99%. Gas exchange func-
tion for this device has recently been described under more
challenging conditions.14 In that study, inlet blood conditions
were set to those from the Food and Drug Administration
‘‘Guidance for Cardiopulmonary Bypass Oxygenators
510(k) Submissions’’ and the standards provided by Ameri-
can National Standards Institute/Association for the
Advancement of Medical Instrumentation/International Or-
ganization for Standardization 7199.27,28 These were, in
part, hemoglobin ¼ 12  1 g/dL, oxygen saturati-
on ¼ 65%  5%, and carbon dioxide tension ¼ 45  5
mm Hg. With these inlet conditions, outlet oxyhemoglobin
saturation was greater than 99% and partial pressure of
oxygen was at least 243 mm Hg with up to 7 L/min of
blood flow. The resulting oxygen transfer at 7 L/min was
395 mL/min. The CO2 transfer was not examined.
However, CO2 transfer is typically excessive in these
devices, requiring CO2 to be added into the sweep gas.
7
This level of gas transfer is more than sufficient for this
application.
CONCLUSIONS
The cTAL tested in the current study had a resistance
well below previous TALs at all flow rates tested and
maintained adequate gas exchange under all conditions.The Journal of Thoracic and CarDespite this, flow diversion to the device should be limited
to less than 60% of CO in the PA-PA setting to minimize
changes in pulmonary hemodynamics. However, further
study is required to determine the effect of PA-PA attach-
ment in conscious sheep. Ultimately, if the cTAL can be
used in the PA-PA configuration with minimal alteration
in hemodynamics, systemic embolic complications could
be eliminated.References
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